Clinical Trial Update: A Long-Term Study of the Safety and Tolerability of Repeated Administration of CEP-33457 in Participants With Systemic Lupus Erythematosus [Phase 3]

View source ↗

Summary

Phase 3 long-term safety and tolerability study of repeated CEP-33457 administration in systemic lupus erythematosus has been terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• CEP-33457

Snippet

Sponsor: Cephalon, Inc. | Conditions: Systemic Lupus Erythematosus | Phase 3 | Status: TERMINATED | Results posted: 2022-12-30